TrialJournal of the American Heart Association2024

Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial.

Zhong Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.